Pharmacotherapy for amyotrophic lateral sclerosis: a review of approved and upcoming agents

SA Johnson, T Fang, F De Marchi, D Neel… - Drugs, 2022 - Springer
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder
involving loss of upper and lower motor neurons, with most cases ending in death within 3–5 …

The clinical trial landscape in amyotrophic lateral sclerosis—Past, present, and future

HJ Wobst, KL Mack, DG Brown… - Medicinal research …, 2020 - Wiley Online Library
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease marked by
progressive loss of muscle function. It is the most common adult‐onset form of motor neuron …

[HTML][HTML] New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022

JS Jiang, Y Wang, M Deng - Frontiers in pharmacology, 2022 - frontiersin.org
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that
primarily affects motor neurons in the brain and spinal cord. In the recent past, there have …

Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs

MK Jaiswal - Medicinal Research Reviews, 2019 - Wiley Online Library
Over the past decades, a multitude of experimental drugs have been shown to delay
disease progression in preclinical animal models of amyotrophic lateral sclerosis (ALS) but …

Therapeutic development in amyotrophic lateral sclerosis

M Bucchia, A Ramirez, V Parente, C Simone… - Clinical …, 2015 - Elsevier
Purpose Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease in
adults. It is almost invariably lethal within a few years after the onset of symptoms. No …

Improving clinical trial outcomes in amyotrophic lateral sclerosis

MC Kiernan, S Vucic, K Talbot, CJ McDermott… - Nature Reviews …, 2021 - nature.com
Individuals who are diagnosed with amyotrophic lateral sclerosis (ALS) today face the same
historically intransigent problem that has existed since the initial description of the disease in …

Current and emerging treatments for amyotrophic lateral sclerosis

S Zoccolella, A Santamato… - … disease and treatment, 2009 - Taylor & Francis
Background: Amyotrophic lateral sclerosis (ALS) is a relatively rare neurodegenerative
disorder of both upper and lower motoneurons. Currently, the management of ALS is …

Amyotrophic lateral sclerosis: recent advances and future therapies

N Nirmalananthan, L Greensmith - Current opinion in neurology, 2005 - journals.lww.com
In the past few years, significant advances have been made in both our understanding of
amyotrophic lateral sclerosis pathogenesis and the development of new therapeutic …

ALS drug development: reflections from the past and a way forward

S Aggarwal, M Cudkowicz - Neurotherapeutics, 2008 - Springer
Tremendous advances in our understanding of pathogenesis of amyotrophic lateral
sclerosis (ALS) have provided a rich pipeline of drugs for clinical trialists. At least 32 unique …

Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation

RJ Mead, N Shan, HJ Reiser, F Marshall… - Nature Reviews Drug …, 2023 - nature.com
Amyotrophic lateral sclerosis (ALS) is a devastating disease caused by degeneration of
motor neurons. As with all major neurodegenerative disorders, development of disease …